Morphosys develops and applies innovative technologies for discovery of disease related targets and new drugs. Focus is on fully human antibodies for research and therapy

MorphoSys develops and applies innovative technologies in order to discover disease related targets and new drugs. The Company's technologies emphasize the use of fully human antibodies in both research and therapeutic applications. Foremost among these technologies is HuCAL®, the Human Combinatorial Antibody Library, a collection of more than 10 billion distinct fully human antibodies. Established in 1992, MorphoSys has led the emergence of the biotechnology sector in Germany and now plays a key role globally in the human antibody sector. The Company has partnered with numerous pharmaceutical and biotechnology companies, currently including Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Centocor Inc./Johnson & Johnson, F. Hoffmann-La Roche AG, GPC Biotech AG, ImmunoGen Inc., Oridis Biomed GmbH, Pfizer Inc., Schering AG and XOMA Ltd.

For full information, visit our website www.morphosys.com